Axsome Therapeutics (AXSM) Receives a Buy from William Blair


William Blair analyst Myles Minter reiterated a Buy rating on Axsome Therapeutics (AXSM) on December 8. The company’s shares closed last Friday at $79.32.

According to TipRanks.com, Minter is a 4-star analyst with an average return of 24.6% and a 65.8% success rate. Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Minerva Neurosciences, and Prevail Therapeutics.

Currently, the analyst consensus on Axsome Therapeutics is a Moderate Buy with an average price target of $134.50, which is a 65.8% upside from current levels. In a report issued on December 2, H.C. Wainwright also reiterated a Buy rating on the stock with a $210.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $109.94 and a one-year low of $35.44. Currently, Axsome Therapeutics has an average volume of 360.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts